Diagnostic testing company Sebia has closed the acquisition of Orgentec Diagnostika, a speciality diagnostics company of Water Street Healthcare Partners.

Water Street has initially invested in Orgentec in 2014 and has transformed Orgentec into a speciality diagnostic solutions provider for autoimmune and infectious diseases.

It has facilitated Orgentec’s acquisition of Arotec Diagnostics, and Corgenix Medical, along with expanding its distribution network, enhancing its sales and marketing.

The acquisitions offered access to important antigens required for autoimmune testing, and the expansion boosted its global reach to customers in over 100 countries.

Also, Water Street has invested in optimising Orgentec’s research and development capabilities to develop next-generation diagnostic instruments and solutions.

The acquisition of Orgentec Diagnostika will help Sebia to expand its capabilities in autoimmunity, infectious diseases, companion diagnostics and clinical trials.

Water Street partner Robert Womsley said: “We’re pleased that our partnership with Orgentec resulted in achieving our shared goal of building the company into one of the world’s premier speciality diagnostic providers.

“The company is making an incredibly positive impact in helping health care providers identify and treat diseases that are some of the hardest to diagnose.

“We’re also pleased that we have found an excellent home for Orgentec in Sebia, which shares our and Orgentec’s deep commitment to advancing speciality diagnostics.”

Water Street claimed that it has worked with global healthcare companies, including Humana, Johnson & Johnson, Medtronic and Walgreen Co.

Also, it has completed more than 100 investments and acquisitions to build more than 30 companies in life sciences, medical products & diagnostics, and health care services.

Water Street has teamed up with founders and owners in the diagnostics sector to build anatomic pathology services, laboratory testing, and diagnostic devices companies.